Company Overview of Sound Pharmaceuticals, Inc.
Sound Pharmaceuticals, Inc., a biopharmaceutical company, develops prescription drugs that enable doctors and patients to prevent and treat hearing loss. It focuses on developing drug treatments for sensori-neural hearing loss. Sound Pharmaceuticals, Inc. was incorporated in 2001 and is based in Seattle, Washington.
4010 Stone Way North
Seattle, WA 98103
Founded in 2001
Key Executives for Sound Pharmaceuticals, Inc.
Compensation as of Fiscal Year 2014.
Sound Pharmaceuticals, Inc. Key Developments
Sound Pharmaceuticals, Inc. Submits Phase 2 Clinical Trial Data on SPI-1005 for the Prevention and Treatment of Sensorineural Hearing Loss
Feb 18 14
Sound Pharmaceuticals has submitted a scientific abstract for presentation at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting in Orlando FL. The Phase 2 clinical trial enrolled 83 subjects with normal hearing or slight hearing loss in an iPod(R) music protocol that induces a slight but temporary hearing loss or threshold shift (TTS). Subjects were randomized in a double-blinded manner to either placebo or three different dosages of SPI-1005 and treated before, during, and after the music exposure. Repeated hearing tests were conducted to determine the incidence, severity and duration of the TTS over the course of one week. The data indicate that SPI-1005 treatment dramatically reduced the incidence, severity and duration of the TTS induced by loud sound vs placebo controls. In addition, all doses of SPI-1005 were well tolerated with no observed or reported adverse events related to study drug. SPI-1005 is an oral capsule that contains ebselen, a novel molecule that mimics and induces the activity of Glutathione Peroxidase, a critical enzyme in the inner ear that protects it from damage caused by loud sounds or noise. In preclinical studies, ebselen treatment was shown to reduce the TTS and permanent threshold shift caused by intense noise exposure or ototoxic drug exposure such as cancer chemotherapy.
Sound Pharmaceuticals Completes its First Phase 2 Clinical Trial with SPI-1005 Involving iPod or Noise Induced Hearing Loss
Nov 5 13
Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod(R) and insert earphones. The sound level was established based on prior human studies where a slight temporary auditory threshold shift (TTS) was safely induced. The listeners were randomized to either placebo or SPI-1005 and treated before and after music exposure. The level of TTS was determined at several time points after the music exposure and all subjects and investigators were blinded to the intervention. SPI-1005 is an oral capsule that contains ebselen, a synthetic molecule that mimics and induces the activity of Glutathione Peroxidase (GPx), a critical enzyme in the inner ear that protects it from damage caused by loud sounds or noise. In preclinical studies, ebselen treatment was shown to improve GPx levels within critical cochlear structures thereby reducing the TTS induced by intense noise. Ebselen is also under clinical investigation for chemotherapy induced ototoxicity in adult cancer patients, a disease that involves both hearing loss and tinnitus.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries